Bracco's ProHance wins new indications

Article

Bracco Diagnostics has received new indications from the Foodand Drug Administration for head and neck and pediatric CNS imagingfor its ProHance MRI agent. ProHance has been approved for usein children two years of age and older for MRI of the brain,

Bracco Diagnostics has received new indications from the Foodand Drug Administration for head and neck and pediatric CNS imagingfor its ProHance MRI agent. ProHance has been approved for usein children two years of age and older for MRI of the brain, spineand associated tissues at a dose of 0.1 mmol/kg. It is also nowindicated for the visualization of extracranial and extraspinalpathology of the head and neck region in adults at a dose of 0.1mmol/kg. Bracco Diagnostics is based in Princeton, NJ, and wasformed when Italy's Bracco bought Squibb Diagnostics.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.